La cadena de opciones muestra datos clave de las opciones de acciones de Agilon Health a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Agilon Health..

Agilon Health (NYSE:AGL) Bolsa, Cadena de Opciones

Agilon Health

Agilon Health Inc is transforming healthcare by empowering primary care physicians for the health of the patients. The company enables physicians to create their own Medicare-centric globally capitated line of business. The company derives its revenue from Medical services.

Agilon Health Inc

T2 Metals Corp

Adventure Gold - United States Dollar

AUSTRAL GOLD LTD ORD by Austral Gold Ltd.

Austral Gold Ltd

ANGELALIGN TECH INC by Angelalign Technologies Inc.

Angelalign Technology Inc

AGL Energy Ltd

AGILITY REAL EST NEW by Agility Real Estate Inc.

Agility Real Estate Inc

ANGEL TELECOM CORP by Angel Telecom Corp.

AgileThought Inc

ATLANTIS GLORY INC by Atlantis Glory Inc.

Atlantis Glory Inc

WIIM

FCEL

FuelCell Energy shares are trading higher after the company announced plans to build a 7.4 MW fuel cell power plant in Hartford, Connecticut, expected to add over $160 million to its generation backlog.

HC Wainwright &amp; Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVBP#NASDAQ">AVBP</a>) with a Buy and raises the price target from $36 to $39.

News

Price Target

Analyst Ratings

AVBP

HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Raises Price Target to $39

ALLY

Ally Financial shares are trading higher after the company reported better-than-expected Q4 financial results and announced it will divest its credit card unit to CardWorks.

Deutsche Bank analyst Steve Powers maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $80 to $78.

Deutsche Bank Maintains Hold on Estee Lauder Cos, Lowers Price Target to $78

Financing

IESC

IES Announced That It Has Amended And Restated Its Existing Credit And Security Agreement, Increasing The Commitment Amount Of The Revolving Credit Facility To $300M From $150M And Extending The Maturity Date To January 21, 2030 While Expanding The Size Of The Lending Group

Deutsche Bank analyst Steve Powers maintains PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) with a Buy and lowers the price target from $184 to $178.

Deutsche Bank Maintains Buy on PepsiCo, Lowers Price Target to $178

Macquarie analyst Tim Nollen maintains Netflix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a Outperform and raises the price target from $965 to $1150.

NFLX

Macquarie Maintains Outperform on Netflix, Raises Price Target to $1150

Deutsche Bank analyst Stephen Powers maintains Mondelez International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDLZ#NASDAQ">MDLZ</a>) with a Hold and lowers the price target from $67 to $62.

MDLZ

Deutsche Bank Maintains Hold on Mondelez International, Lowers Price Target to $62

RVSN

Rail Vision Announced The Signing Of A Binding Memorandum Of Understanding With Sujan Ventures, A Division Of The Esteemed Sujan Group To The Indian Rail Industry

Northland Capital Markets analyst Michael Latimore maintains Gorilla Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) with a Outperform and raises the price target from $13 to $18.

GRRR

Northland Capital Markets Maintains Outperform on Gorilla Tech Gr, Raises Price Target to $18

Barclays analyst Jason Goldberg maintains Zions Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZION#NASDAQ">ZION</a>) with a Underweight and raises the price target from $59 to $61.

ZION

Barclays Maintains Underweight on Zions Bancorp, Raises Price Target to $61

Northland Capital Markets analyst Gus Richard reiterates Seagate Tech Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STX#NASDAQ">STX</a>) with a Outperform and raises the price target from $144 to $160.

Reiteration

Northland Capital Markets Reiterates Outperform on Seagate Tech Hldgs, Raises Price Target to $160

REKR

Rekor Systems' AI-Powered Scout Platform Secures Role In $13M New Jersey Public Safety Upgrade

AGYS

Agilysys shares are trading lower after the company reported worse-than-expected Q3 sales results and issued FY25 revenue guidance below estimates.

HC Wainwright &amp; Co. analyst Robert Burns maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Buy and raises the price target from $17 to $21.

REPL

HC Wainwright & Co. Maintains Buy on Replimune Group, Raises Price Target to $21

Barclays analyst Nicholas Campanella maintains Xcel Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XEL#NASDAQ">XEL</a>) with a Overweight and lowers the price target from $71 to $69.

Barclays Maintains Overweight on Xcel Energy, Lowers Price Target to $69

Barclays analyst Benjamin Budish maintains Charles Schwab (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) with a Overweight and raises the price target from $95 to $96.

SCHW

Barclays Maintains Overweight on Charles Schwab, Raises Price Target to $96

COHR

Coherent Announces The Launch Of New Pin-hole Array Biochips For Medical Diagnostics, With A Focus On Gene Sequencing Applications

Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) (the "Group" or "Super Group"), the parent company of Betway, a leading online sports betting and gaming business and Spin, the multi-brand online casino, today provided an update on its preliminary, unaudited fourth quarter and full-year 2024 performance.
The Group is pleased to announce that Q4 2024 is expected to be its strongest ever ex-US quarter with Total Revenue of ~€486 million and Adjusted EBITDA, a non-GAAP financial measure, of between €125 million and €130 million. During the quarter the Group projects to have set a number of new monthly ex-US records, with December being particularly impressive, achieving new highs for deposits and Total Revenue.
For the full-year, the Group expects to have surpassed its previously issued ex-US guidance targets of Total Revenue of €1.60 billion and Adjusted EBITDA of greater than €360 million.
New ex-US records were also expected to have been achieved in 2024 for both Total Revenue and Adjusted EBITDA, with Total Revenue growing by ~18% to ~€1.66 billion and Adjusted EBITDA growing by more than 50%, anticipated to be between €387 million and €392 million, a margin of greater than 23%.
The developing U.S. business is also anticipated to have delivered new records in the fourth quarter – October was an all-time high for Total Revenue, which was subsequently surpassed in both November and December. The expected Q4 2024 investment into the U.S. business is ~€11 million, which would bring the total investment for the year to ~€61 million. Given the reduced footprint and sole focus on iGaming in the U.S., this investment is expected to reduce materially in 2025.

Guidance

SGHC

Super Group Expects Q4 Revenue Of ~€486M Vs €404.65M Est, FY24 Revenue Of ~€1.66B Vs ~€1.613B Est

HC Wainwright &amp; Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGEN#NASDAQ">AGEN</a>) from Neutral to Neutral.

AGEN

HC Wainwright & Co. Reiterates Neutral on Agenusto Neutral

Bernstein analyst Lance Wilkes initiated coverage of Agilon Health (AGL) with a Market Perform rating and $2.50 price target The company has enjoye...

Agilon Health initiated with a Market Perform at Bernstein

Macquarie initiated coverage of Agilon Health (AGL) with a Neutral rating and $3 price target Agilon health is a pioneer of value-based care with s...

Agilon Health initiated with a Neutral at Macquarie

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Netflix, MongoDB downgraded: Wall Street's top analyst calls

Worst performing stocks for tax loss selling – Wolfe

In a report released on January 8, Sean Dodge from RBC Capital maintained a Buy rating on Agilon Health (AGL – Research Report), with a price targe...

RBC Capital Reaffirms Their Buy Rating on Agilon Health (AGL)

Citi upgraded Agilon Health (AGL) to Neutral from Sell with a price target of $2.25, up from $1.75. The firm sees limited further downside to the s...

Agilon Health upgraded to Neutral from Sell at Citi

HIMS downgraded, agilon upgraded at Citi in 2025 Health Tech review

Stifel Nicolaus analyst Michael Craig Jones downgraded Agilon Health (AGL – Research Report) to a Hold on January 10 and set a price target of $2.0...

Agilon Health (AGL) was downgraded to a Hold Rating at Stifel Nicolaus

Bernstein analyst Lance Wilkes maintained a Hold rating on Agilon Health (AGL – Research Report) today and set a price target of $3.15. The company...

Bernstein Sticks to Their Hold Rating for Agilon Health (AGL)

Bernstein analyst Lance Wilkes raised the firm's price target on Agilon Health (AGL) to $3.15 from $2.50 on the back of higher MA rate, while keepi...

Agilon Health price target raised to $3.15 from $2.50 at Bernstein

ACHC

ACLS

AGCO

ALGM

AMKR

APLS

ASTH

ATKR

BIIB

BMRN

BRBR

CLVT

CNXC

COLD

DINO

DXCM

ENPH

FIVN

FLNC

HIMS

INTC

IONS

IPGP

LFST

MCHP

MRNA

MTCH

NEOG

NTAP

OKTA

OPCH

PRVA

PTEN

QDEL

QRVO

REGN

REXR

SEDG

SGRY

STNE

SWKS

SYNA

WOLF

XRAY

Press Releases

agilon health to Participate at 2024 Wells Fargo Healthcare Conference

AGILON HEALTH INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of agilon health, inc. - AGL

AGILON HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of agilon health, inc. - AGL

agilon health Sets Date to Report Third Quarter 2024 Financial Results

Legal

AGILON ALERT: Bragar Eagel & Squire, P.C. is Investigating Agilon Health, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

agilon health to Participate at 2024 Wolfe Research Healthcare Conference

agilon health Reports Third Quarter 2024 Results

agilon health Reports ACO REACH Model Results for 2023 Performance Year

Agilon Health, Inc, B. Riley Financial, Target Corporation, and Getty Images Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

GETY

RILY

Addus HomeCare Corporation - Common Stock

Addus HomeCare

Amedisys

AMN Healthcare Services

Astrana Health

BrightSpring Health Services, Inc. - Common Stock

BrightSpring Health

Chemed

Cigna

CorVel

CVS Health

Quest Diagnostics Incorporated Common Stock

Quest Diagnostics

DaVita

Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)

Comments

Agilon Health

Agilon Health (AGL) Opciones

Agilon Health (NYSE:AGL) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL